An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers

Clinical Therapeutics

Volumn 32, Issue 7, 2010, Pages 1372-1386

  Tomkinson, Helen K ^a   Kemp, John V ^a   Wollseifen, Thomas ^b   Morris, Thomas ^a   Oliver, Stuart D ^a  

^a ASTRAZENECA   (United Kingdom)

^b PAREXEL INTERNATIONAL   (United States)

Author keywords

CYP3A4; Midazolam; Pharmacokinetics; Prostate cancer; ZD4054; Zibotentan

Indexed keywords

1 HYDROXY MIDAZOLAM; 4 HYDROXY MIDAZOLAM; CYTOCHROME P450 3A4; DRUG METABOLITE; MIDAZOLAM; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; UNCLASSIFIED DRUG;

ACCOMMODATION DISORDER; ADULT; AREA UNDER THE CURVE; ARTICLE; ATTENTION DISTURBANCE; BLURRED VISION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG POTENCY; DRUG SAFETY; EAR DISEASE; ERYTHEMA; EUPHORIA; FACE EDEMA; FATIGUE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERHIDROSIS; LIMB PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; NOSE CONGESTION; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOPHLEBITIS; VERTIGO; XEROSTOMIA;

ADULT; ANTI-ANXIETY AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME INHIBITORS; HEADACHE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDAZOLAM; MIDDLE AGED; PYRROLIDINES; TIME FACTORS;

EID: 77955262859     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.07.013     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009, 59:225-249.
2. McDavid K, Lee J, Fulton JP, et al. Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Rep. 2004, 119:174-186.
3. Petrylak D Therapeutic options in androgen-independent prostate cancer: Building on docetaxel. BJU Int. 2005, 96(Suppl 2):41-46.
4. Kasper S, Cookson MS Mechanisms leading to the development of hormone-resistant prostate cancer. Urol Clin North Am. 2006, 33:201-210. vii.
5. Kasper S, Cookson MS Mechanisms leading to the development of hormone-resistant prostate cancer. Urol Clin North Am. 2006, 33:vii.
6. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004, 351:1513-1520.
7. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004, 351:1502-1512. TAX 327 Investigators.
8. Bagnato A, Natali PG Targeting endothelin axis in cancer. Cancer Treat Res. 2004, 119:293-314.
9. Nelson J, Bagnato A, Battistini B, Nisen P The endothelin axis: Emerging role in cancer. Nat Rev Cancer. 2003, 3:110-116.
10. Nelson JB, Udan MS, Guruli G, Pflug BR Endothelin-1 inhibits apoptosis in prostate cancer. Neoplasia. 2005, 7:631-637.
11. Morris CD, Rose A, Curwen J, et al. Specific inhibition of the endothelin A receptor with ZD4054: Clinical and preclinical evidence. Br J Cancer. 2005, 92:2148-2152.
12. Bagnato A, Spinella F Emerging role of endothelin-1 in tumor angiogenesis. Trends Endocrinol Metab. 2003, 14:44-50.
13. Bagnato A, Rosanò L Epithelialmesenchymal transition in ovarian cancer progression: A crucial role for the endothelin axis. Cells Tissues Organs. 2007, 185:85-94.
14. Rosanò L, Varmi M, Salani D, et al. Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res. 2001, 61:8340-8346.
15. Guise TA, Yin JJ, Mohammad KS Role of endothelin-1 in osteoblastic bone metastases. Cancer. 2003, 97(Suppl 3):779-784.
16. Okazawa M, Shiraki T, Ninomiya H, et al. Endothelin-induced apoptosis of A375 human melanoma cells. J Biol Chem. 1998, 273:12584-12592.
17. Godara G, Cannon GW, Cannon GM, et al. Role of endothelin axis in progression to aggressive phenotype of prostate adenocarcinoma. Prostate. 2005, 65:27-34.
18. Gohji K, Kitazawa S, Tamada H, et al. Expression of endothelin receptor a associated with prostate cancer progression. J Urol. 2001, 165:1033-1036.
19. Rosanò L, Di Castro V, Spinella F, et al. ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation. Exp Biol Med (Maywood). 2006, 231:1132-1135.
20. Smollich M, Götte M, Fischgräbe J, et al. ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole. Breast Cancer Res Treat 2009 Nov 27, [Epub ahead of print.].
21. Growcott JW Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054. Anticancer Drugs. 2009, 20:83-88.
22. James ND, Caty A, Borre M, et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: A double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol. 2009, 55:1112-1123.
23. Swaisland HC, Oliver SD, Morris T, et al. In vitro metabolism of the specific endothelin-A receptor antagonist ZD4054 and clinical drug interactions between ZD4054 and rifampicin or itraconazole in healthy male volunteers. Xenobiotica. 2009, 39:444-456.
24. Guengerich FP Cytochrome P-450 3A4: Regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol. 1999, 39:1-17.
25. Chung E, Nafziger AN, Kazierad DJ, Bertino JS Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin Pharmacol Ther. 2006, 79:350-361.
26. Olkkola KT, Ahonen J Midazolam and other benzodiazepines. Handb Exp Pharmacol. 2008, 335-360.
27. Cytochrome P450: Structure, Mechanism and Biochemistry 1995, Springer-Verlag, New York, NY. P.R. Ortiz De Montellano (Ed.).
28. Guidance for Industry: Drug interaction studies-study design, data analysis, and implications for dosing and labelling US Dept of Health and Human Services, Food and Drug Administration (FDA)Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER)Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER)Center for Biologics Evaluation and Research (CBER), Accessed June 29, 2010. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf.
29. The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, Committee for Proprietary Products 9CPMP0: Note for guidance on the investigation of drug interactions Accessed June 29, 2010. http://www.ema.europa.eu/pdfs/human/ewp/056095en.pdf.
30. WMA Declaration of Helsinki. Ethical principles for medical research involving human subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland June 1964, World Medical Association (WMA), Accessed June 29, 2010. http://www.wma.net/en/30publications/10policies/b3/index.html.
31. ICH topic E6 (R1): Guideline for good clinical practice. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use European Medicines Agency (EMEA), Accessed June 29, 2010. http://www.ema.europa.eu/pdfs/human/ich/013595en.pdf.
32. Rowland M, Tozer TN Clinical Pharmacokinetics: Concepts and Applications 1995, Williams & Wilkins, Baltimore, Md. 3rd ed.
33. Senn S Cross-over Trials in Clinical Research 2002, J Wiley, Chichester, UK. 2nd ed.
34. Tomkinson HK, Kemp J, Hurewitz S, et al. Relative bioavailability of zibotentan (ZD4054) immediate release tablets compared with a reference oral formulation: A Phase I study in healthy male volunteers. AAPSJ. 2009, 11(Suppl 2):771.
35. Nordt SP, Clark RF Midazolam: A review of therapeutic uses and toxicity. J Emerg Med. 1997, 15:357-365.